Lentiviral Vectors CDMO Solution
Lentiviral Vector CDMO Features
GMP-compliant lentiviral vector manufacturing and development services supporting cell and gene therapy from research to clinical production.
Vector Design & Safety
- Third-generation lentiviral vector systems
- Quad-plasmid configuration
- Enhanced viral safety profile
- Regulatory submission readiness
GMP Manufacturing
- Serum-free 293T suspension culture
- Single-use bioreactors
- Scalable production from 10 L to 100 L
- High-titer lentiviral vectors
Transduction Performance
- High efficiency at low MOI
- Low vector copy number (VCN)
- Optimized for large gene inserts
- Validated in immune cell therapies
Therapeutic Applications
- CAR-T and UCAR-T therapies
- CAR-NK and iPSC-derived NK cells
- TCR-T cell therapies
- HSC gene therapy programs
Lentiviral Vector CDMO Features
GMP-compliant lentiviral vector manufacturing and development services supporting cell and gene therapy from research to clinical production.
Vector Design & Safety
- Third-generation lentiviral vector systems
- Quad-plasmid configuration
- Enhanced viral safety profile
- Regulatory submission readiness
GMP Manufacturing
- Serum-free 293T suspension culture
- Single-use bioreactors
- Scalable production from 10 L to 100 L
- High-titer lentiviral vectors
Transduction Performance
- High efficiency at low MOI
- Low vector copy number (VCN)
- Optimized for large gene inserts
- Validated in immune cell therapies
Therapeutic Applications
- CAR-T and UCAR-T therapies
- CAR-NK and iPSC-derived NK cells
- TCR-T cell therapies
- HSC gene therapy programs
Lentiviral Vector Suspension System
- Virus Expressed 293T serum-free culture technology
- Disposable bioreactors
- Yield: Up to 2E11TU/50L
- Scale: From 10L up to 100L
Transduction Effect
Different GOI lengths, at a lower MOI, can obtain a high positive rate, low copy number of the cell products

- Can be applied to different cells
- CAR-T therapy for Solid tumors
- TCR-T cell therapeutics
- Gene-edited HSCs
- UCAR-T cell therapeutics
- CAR-NK cell therapeutics
- iPS-CAR -NK cell therapeutics
Lentiviral Vector RNA Copy Number Detection Kit
Product Overview
Quantification of vector-specific nucleic acids is a reliable approach for estimating the physical titer of lentiviral vectors. The physical titer reflects the total number of viral particles and can be determined by measuring either vector-associated proteins or genomic RNA content.
This kit enables accurate determination of lentiviral vector physical titer by detecting the RNA copy number of the vector genome using TaqMan probe-based quantitative PCR (qPCR).
Principle of Detection
Physical titers of HIV-1–derived lentiviral vectors can be calculated by quantifying p24 capsid protein using ELISA or by measuring genomic RNA copy number using qPCR. This detection kit focuses on RNA-based quantification, providing a direct and sensitive assessment of total viral particle content.
Lentiviral Vector RNA Copy Number Detection Kit
Product Overview
Quantification of vector-specific nucleic acids is a reliable approach for estimating the physical titer of lentiviral vectors. The physical titer reflects the total number of viral particles and can be determined by measuring either vector-associated proteins or genomic RNA content.
This kit enables accurate determination of lentiviral vector physical titer by detecting the RNA copy number of the vector genome using TaqMan probe-based quantitative PCR (qPCR).
Principle of Detection
Physical titers of HIV-1–derived lentiviral vectors can be calculated by quantifying p24 capsid protein using ELISA or by measuring genomic RNA copy number using qPCR. This detection kit focuses on RNA-based quantification, providing a direct and sensitive assessment of total viral particle content.
